Evidence map›Paper›PMID 39143529›Full record

ArticleBMC cancer2024

Combination of transcriptome and Mendelian inheritance reveals novel prognostic biomarker of CTLA-4-related lncRNAs and protective role of nitrogen metabolism pathway in lung adenocarcinoma development.

Huisi Shan, Xiaocong Wang, Fei Yin, Yiting Zhou, Liuhan Mao, Xiao Zhu, Caixin Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huisi Shan *Department of Clinical Laboratory, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, China.
Xiaocong Wang *Department of Pathology, Qingdao Municipal Hospital Group, Qingdao, China.
Fei YinDepartment of Clinical Laboratory, Qingdao Sixth People's Hospital, Qingdao, China.
Yiting ZhouThe Second Affiliated Hospital, Guangdong Medical University, Zhanjiang, China.
Liuhan MaoThe Second Affiliated Hospital, Guangdong Medical University, Zhanjiang, China.
Xiao ZhuThe Second Affiliated Hospital, Guangdong Medical University, Zhanjiang, China. xzhu@gdmu.edu.cn.
Caixin LiuDepartment of Clinical Laboratory, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, China. liucaixin@yjsyy.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSince in the cancer setting, tumor cells may use cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to evade the immune system. This study aimed to identify CTLA-4-related long non-coding RNAs (lncRNAs) and assess their roles in lung adenocarcinoma (LUAD) development.

methodsClinical and genomic data were obtained from The Cancer Genome Atlas (TCGA), MSigDB and Gene Weaver. CTLA-4-related lncRNA-based gene signatures (CTLA4LncSigs) were identified using Cox regression, establishing a risk score model and an independent prognostic model. Enrichment analysis (GO/KEGG) was performed. Mendelian randomization (MR) analysis investigated the nitrogen metabolism and lung cancer relationship, with Bayesian weighted MR (BWMR) addressing uncertainties. Correlations with tumor microenvironment and drug sensitivity were explored.

resultsNineteen CTLA4LncSigs significantly influenced LUAD prognosis. The risk score demonstrated independence as a prognostic factor. Functional analysis revealed lncRNAs' impact on nitrogen metabolism. MR and BWMR confirmed the protective role of the nitrogen metabolism pathway in lung cancer.

conclusionOur study identifies CTLA-4-related lncRNAs associated with LUAD prognosis and uncovers a previously undiscovered protective role of the nitrogen metabolism pathway in combating LUAD development, providing new insights into potential therapeutic targets and prognostic biomarkers for this aggressive cancer subtype.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorCTLA-4 AntigenLung NeoplasmsNitrogenRNA, Long NoncodingFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMendelian Randomization AnalysisMiddle AgedPrognosisTranscriptomeTumor MicroenvironmentBiomarkers, TumorCTLA-4 AntigenCTLA4 protein, humanNitrogenRNA, Long NoncodingCTLA-4-related lncRNA-based signaturesLung adenocarcinomaMendelian randomizationPrognosisTumor microenvironment

Identifiers

PMID39143529
PMCPMC11323378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.